We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Epistem | LSE:EHP | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 85.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGDR
Genedrive PLC
13 December 2017
Hardman Research: Remodelled for growth
Remodelled for growth - genedrive plc is a commercial-stage company focused on point-of-care/need molecular diagnostics and biomarkers. Its Genedrive(R) in vitro diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in infectious disease diagnosis. The rapid and accurate analysis of patient samples aids significantly the clinical decision process, with point-of-need testing particularly important in emerging markets. Hepatitis C diagnosis is a multi-million dollar market opportunity, which is well supported by the WHO and other philanthropic organisations.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/genedrive-plc-documents/13.12.17-remodelled-for-growth.pdf
To contact us: Contacts: mh@hardmanandco.com Hardman & Co Dr Martin dmh@hardmanandco.com 35 New Broad Street Hall gp@hardmanandco.com London Dr Dorothea EC2M 1NH Hill www.hardmanandco.com Dr Gregoire Follow us on Twitter Pave @HardmanandCo +44 20 7194 7622
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKBDNABDDABD
(END) Dow Jones Newswires
December 13, 2017 02:15 ET (07:15 GMT)
1 Year Epistem Chart |
1 Month Epistem Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions